Compugen Gets U.S. Patent

Compugen, a therapeutic discovery company, said the U.S. Patent and Trademark Office (USPTO) has issued a patent for COM701, the company’s lead immuno-oncology therapeutic antibody candidate. The patent relates to the method of using COM701 for activating T cells in cancer patients. Activating T cells results in stimulating the immune system, and therefore could be used for cancer immunotherapy treatment. The patent is expected to expire no earlier than February 2036 in the U.S. for the issued claims.

The patent was issued under the USPTO’s pilot program providing early review for patent applications pertaining to cancer immunotherapy. “The patent is part of our global strategy of immuno-oncology patents and patent applications controlled by our company to protect our IP assets,” said CEO Anat Cohen-Dayag.

By Bryan Smith